Bluebird Bio Inc. (NASDAQ:BLUE)

CAPS Rating: 4 out of 5

BLUE News and Commentary

Caps

How do you think BLUE will perform against the market?

Add Stock to CAPS Watchlist

All Players

248 Outperform
19 Underperform
 

All-Star Players

76 Outperform
9 Underperform
 

Wall Street

5 Outperform
0 Underperform
 

Top BLUE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Exanut (49.57)
Submitted January 17, 2016

They have pulled off what no other company was able to do successfully to date: gene therapy. This is a paradigm shift in treating hereto untreateable diseases. I don't expect the road to be easy as far as investing with this company, but I do think… More

TMFFlygal (99.01)
Submitted December 08, 2015

Selling for a while after the huge drop today, good for a trade

BLUE VS S&P 500 (SPY)

Fools bullish on BLUE are also bullish on:

Fools bearish on BLUE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BLUE.

Recs

0
Member Avatar pehenia (59.47) Submitted: 1/10/2018 11:38:27 PM : Outperform Start Price: $172.90 BLUE Score: -4.33

Gene therapy/editing is the future of medicine. I see the difference between it and current conventional medicine as similar to the difference between manufacturing cars and manufacturing software. You both produce a product, but the margins on software are far superior due to the lower capital investment and ease of distribution. Spending the last decade in cancer therapy (radiation), and previous to that medical devices in general, current medicine is big, slow, expensive, inefficient, needs massive infrastructure, cumbersome, but effective. Gene therapy will be fast, efficient, easy to distribute, lower infrastructure, and just as if not more effective.

Recs

0
Member Avatar MaestroFool (91.14) Submitted: 1/4/2018 12:09:08 PM : Outperform Start Price: $176.25 BLUE Score: -7.27

Bluebird is the gatekeeper in T cell-based immunotherapies for genetic diseases and cancer. In short, they take out your cells and re-engineer them to fight disease. I bought Bluebird bio for my portfolio on 9/22/17 but because I had too many open picks, CAPS wouldn't let me add my green thumb. Anyway, this clinical-stage biotech is already up 39% since then (that's 33% above the market) but I think that tiny gain is small peanuts up against what this biotech could grow to be. The company recently presented promising results of their ongoing clinical trials at the much-anticipated American Society of Hematology annual meeting in Atlanta. They have the backing of big biotech Celgene. And management is smartly raising capital in the open markets with a $690 million offering recently closed. Buckle up for a bumpy ride, though, because this is biotech after all.

Recs

0
Member Avatar ryonjarvis (79.73) Submitted: 12/15/2017 4:24:43 PM : Outperform Start Price: $184.70 BLUE Score: -13.08

Motley Fool Explorer 2018 1 of 4 Biotech plays.

Leaderboard

Find the members with the highest scoring picks in BLUE.

Score Leader

portefeuille12

portefeuille12 (38.70) Score: +731.14

The Score Leader is the player with the highest score across all their picks in BLUE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille12 38.70 4/16/2014 Outperform 5Y $19.11 +781.74% +50.60% +731.14 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 98.83 11/5/2013 Outperform 5Y $20.53 +720.75% +58.88% +661.87 0 Comment
portefeuille2 99.41 4/11/2014 Outperform 5Y $20.74 +712.44% +53.74% +658.70 0 Comment
portefeuille3 98.38 4/11/2014 Outperform 5Y $20.74 +712.44% +53.87% +658.57 0 Comment
portefeuille6 99.74 4/11/2014 Outperform 5Y $20.91 +705.83% +54.07% +651.76 0 Comment
johninmadison 59.42 4/7/2014 Outperform 5Y $21.07 +699.72% +50.44% +649.28 0 Comment
HoosierDoozer 38.52 2/5/2014 Outperform 5Y $20.84 +708.54% +60.00% +648.54 0 Comment
portefeuille 98.83 4/8/2014 Outperform 5Y $21.44 +685.91% +51.71% +634.21 1 Comment
jack0071 73.92 1/8/2014 Outperform 5Y $21.47 +684.82% +52.44% +632.37 0 Comment
jtothes 74.68 2/14/2014 Outperform 3Y $21.88 +670.11% +52.95% +617.16 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBMOCapital < 20 6/6/2017 Outperform NS $95.43 +76.58% +14.93% +61.65 0 Comment
TrackStandpoint 36.68 5/30/2017 Outperform 5Y $78.60 +39.82% +0.31% +39.51 6/16/2017 @ $109.90 0 Comment
TrackJimCramer 85.32 5/27/2015 Outperform 3W $189.69 -11.17% +31.48% -42.65 0 Comment
TrackJimCramer 85.32 3/13/2015 Underperform 3W $119.93 +58.17% +3.34% -54.83 5/27/2015 @ $189.69 0 Comment
TrackPiperJaff 87.39 12/9/2014 Outperform NS $77.42 +117.64% +36.84% +80.80 0 Comment
TrackRothCapital 72.55 9/22/2014 Outperform NS $36.70 +359.13% +39.59% +319.54 0 Comment
TrackJimCramer 85.32 3/20/2014 Outperform 3W $26.83 +347.00% +9.63% +337.37 3/13/2015 @ $119.93 0 Comment
TrackWedbush 87.31 7/15/2013 Outperform NS $32.37 +420.54% +66.49% +354.05 0 Comment

Featured Broker Partners